Population pharmacokinetics of recombinant factor IX: implications for dose tailoring
2013 (English)In: Haemophilia, ISSN 1351-8216, E-ISSN 1365-2516, Vol. 19, no 5, 753-757 p.Article in journal (Refereed) Published
The principles of pharmacokinetic (PK) dose tailoring in clinical practice, using limited blood sampling and Bayesian PK analysis, have been described for factor VIII (FVIII). This study applied the same procedure to recombinant FIX (rFIX), i.e. population PK modelling and the use of a simplified (one-compartment) model to describe only the terminal part of the coagulation factor vs. time curve. Data from a previous study on rFIX in 56 patients (4-56years, 18-133kg) were used to define a three-compartment population PK model. The average FIX clearance was 8.4mLh(-1)kg(-1). Elimination half-life ranged between 14 and 27h. Data obtained from 24h after the infusion were found to define the terminal phase of FIX disposition. Doses to produce a target trough FIX level (set at 0.01IUmL(-1)) at 72h predicted by the Bayesian analysis, with blood sampling at either 24, 48 and 72h or at only 24 and 48h, were within -40% to +67% of those predicted using the three-compartment model, and within -57% to +125% for targeting a level at 96h. These errors were lower than the overall interindividual variance in dose requirements. As three-compartment models are needed to characterize the PK of both plasma-derived FIX and rFIX, simplification to a one-compartment model is less straightforward than for FVIII, and the methodology should be investigated further before clinical application. Limited blood sampling and Bayesian analysis could still, however, be potentially useful for targeting rFIX trough levels during prophylaxis.
Place, publisher, year, edition, pages
2013. Vol. 19, no 5, 753-757 p.
dosing, factor IX, haemophilia B, pharmacokinetics, prophylaxis
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-207506DOI: 10.1111/hae.12188ISI: 000323453200032OAI: oai:DiVA.org:uu-207506DiVA: diva2:648822